De-escalation of antifungal treatment in critically ill patients with suspected invasive Candida infection: incidence, associated factors, and safety

Annals of Intensive Care

Table 4 Factors associated with ICU mortality by Cox proportional hazards models

Factors	Univariate analysis		Multivariate analysis
Factors	HR (95% CI)	p	HR (95% CI)	p
At ICU admission
SAPS II	1.01* (1.004–1.02)	0.005	1.01* (1–1.02)	0.040
Surgical patients	0.46 (0.3–0.69)	< 0.001	–	–
ARDS	1.81 (1.22–2.68)	0.003	–	–
During ICU stay
Renal replacement therapy	1.64 (1.1–2.47)	0.018	–	–
Preemptive antifungal treatment	0.50 (0.32–0.80)	0.004	–	–
Apyrexia > 72 h	0.36 (0.23–0.57)	< 0.001	–	–
Catecholamine withdrawal at 72 h	0.35 (0.27–0.52)	< 0.001	0.47 (0.29–0.76)	0.002
De-escalation of antifungal treatment**	0.75 (0.44–1.26)	0.28	–	–

ICU intensive care medicine, SAPS simplified acute physiology score, ARDS acute respiratory distress syndrome
* Per point of SAPS II; HR hazard ratio, CI confidence interval
** De-escalation of antifungal treatment was forced in the final Cox model